About
Immunotherapies
Areas of Focus
Categories
Biologics & BiopharmaceuticalBoston & New England
Team (10)
Adam Cutler
Adam Cutler
Mural Oncology
team_member
Benjamin Hickey
Benjamin Hickey, MBA
Mural Oncology
team_member
Caroline Loew
Caroline Loew, Ph.D.
Mural Oncology
team_member
Francis Cuss
Francis Cuss, M.B., B.Chir., FRCP
Mural Oncology
team_member
George Golumbeski
George Golumbeski, Ph.D.
Mural Oncology
team_member
Justin Levine
Justin Levine
Mural Oncology
team_member
Clinical Trials (6)
View allTotal Trials
6
As Lead Sponsor
6
As Collaborator
0
Total Enrollment
1,080
By Phase
PHASE3: 1PHASE2: 2PHASE1/PHASE2: 3
By Status
COMPLETED: 3TERMINATED: 2ACTIVE_NOT_RECRUITING: 1
Clinical Trials Pipeline6 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Today
Hover over trial bars to see details
Recent Trials
NCT05092360Lead Sponsor
Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)
PHASE3Terminated
456 participants
Started: Jan 10, 2022 · Completed: May 8, 2025
NCT04830124Lead Sponsor
Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6
PHASE2Terminated
173 participants
Started: Sep 27, 2021 · Completed: May 8, 2025
NCT04592653Lead Sponsor
Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3)
PHASE1/PHASE2Active, not recruiting
78 participants
Started: Sep 30, 2020 · Completed: Dec 31, 2024
NCT04144517Lead Sponsor
A Study of ALKS 4230 (Nemvaleukin Alfa) With Pembrolizumab in Head and Neck Cancer
PHASE2Completed
14 participants
Started: Feb 5, 2020 · Completed: Jan 7, 2022
NCT03861793Lead Sponsor
A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)
PHASE1/PHASE2Completed
116 participants
Started: Feb 26, 2019 · Completed: Mar 1, 2023
Locations (1)
Headquarters
Waltham, MA, United States
Map
Loading map...